Aclaris Therapeutics, Inc. (ACRS): Price and Financial Metrics
Today's Latest Price: $3.82 USD
Oct 29 1:40pm Add ACRS to Watchlist Sign Up
ACRS Stock Summary ACRS's price/sales ratio is 29.51; that's higher than the P/S ratio of 94.24% of US stocks. With a year-over-year growth in debt of -63.83%, Aclaris Therapeutics Inc's debt growth rate surpasses merely 3.75% of about US stocks. As for revenue growth, note that ACRS's revenue has grown -65.86% over the past 12 months; that beats the revenue growth of just 2.71% of US companies in our set. Stocks that are quantitatively similar to ACRS, based on their financial statements, market capitalization, and price volatility, are RESN, CUE, ZYME, IONS, and CLLS. ACRS's SEC filings can be seen here. And to visit Aclaris Therapeutics Inc's official web site, go to www.aclaristx.com.
ACRS Price/Volume Stats
Aclaris Therapeutics, Inc. (ACRS) Company Bio
Aclaris Therapeutics, Inc. is a clinical-stage specialty pharmaceutical company focused on identifying, developing, and commercializing novel drugs to address unmet needs in dermatology. The company was founded in 2012 and is based in Malvern, Pennsylvania.
ACRS Latest News Stream
All News Types
Acquisition Commentary Earnings IPOs New Coverage (Bullish) Product News PT Lowered PT Raised PT Set (Bullish) Rating Reiterated (Bullish) Resumes Coverage (Bullish) Stock Offering
Loading, please wait...
Latest ACRS News From Around the Web
Below are the latest news stories about Aclaris Therapeutics Inc that investors may wish to consider to help them evaluate ACRS as an investment opportunity.
The following slide deck was published by Aclaris Therapeutics, Inc. in conjunction with this event....
WAYNE, Pa., Sept. 01, 2020 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on…
• First Subject Dosed in Phase 2a Trial of ATI-450, an Investigational Oral MK2 Inhibitor, as a Potential Treatment for Moderate to Severe Rheumatoid …
Aclaris (ACRS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
DUBLIN--(BUSINESS WIRE)--The "Seborrhea Pipeline Research Monitor, 2020 - Drugs, Companies, Clinical Trials, R&D Pipeline Updates, Status and Outlook" report has been added to ResearchAndMarkets.com's offering. PIPELINE HIGHLIGHTS Seborrhea is one of the widely researched conditions during 2020 with 4 companies actively focusing on realizing pipeline's potential. Development of Seborrhea medicines is identified as integral to the strategy of the majority of companies operating in the indust
Read More 'ACRS' Stories Here
ACRS Price Returns
Get Free Updates
Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!
Page generated in 0.8427 seconds.